BR0210898A - Formulação farmacêutica, dose unitária da mesma, uso de pulvestrante na preparação de uma formulação farmacêutica, e, seringa ou frasco estéril - Google Patents

Formulação farmacêutica, dose unitária da mesma, uso de pulvestrante na preparação de uma formulação farmacêutica, e, seringa ou frasco estéril

Info

Publication number
BR0210898A
BR0210898A BR0210898-4A BR0210898A BR0210898A BR 0210898 A BR0210898 A BR 0210898A BR 0210898 A BR0210898 A BR 0210898A BR 0210898 A BR0210898 A BR 0210898A
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
preparation
unit dose
vial
powder
Prior art date
Application number
BR0210898-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Julie Kay Cahill
Paul Richard Gellert
Alan Marshall Irving
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0116619.8A external-priority patent/GB0116619D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0210898A publication Critical patent/BR0210898A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
BR0210898-4A 2001-07-07 2002-07-03 Formulação farmacêutica, dose unitária da mesma, uso de pulvestrante na preparação de uma formulação farmacêutica, e, seringa ou frasco estéril BR0210898A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0116619.8A GB0116619D0 (en) 2001-07-07 2001-07-07 Formulation
US31571101P 2001-08-30 2001-08-30
PCT/GB2002/003092 WO2003006064A1 (en) 2001-07-07 2002-07-03 Pharmaceutical formulation for the intramuscular administration of fulvestrant

Publications (1)

Publication Number Publication Date
BR0210898A true BR0210898A (pt) 2004-06-22

Family

ID=26246290

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210898-4A BR0210898A (pt) 2001-07-07 2002-07-03 Formulação farmacêutica, dose unitária da mesma, uso de pulvestrante na preparação de uma formulação farmacêutica, e, seringa ou frasco estéril

Country Status (15)

Country Link
EP (1) EP1406662A1 (is)
JP (1) JP2004534093A (is)
CN (1) CN1553815A (is)
AR (1) AR037138A1 (is)
BR (1) BR0210898A (is)
CA (1) CA2453111A1 (is)
CO (1) CO5560585A2 (is)
HU (1) HUP0400115A3 (is)
IL (1) IL159576A0 (is)
IS (1) IS7097A (is)
MX (1) MXPA04000028A (is)
NO (1) NO20040047L (is)
PL (1) PL367624A1 (is)
RU (1) RU2004102393A (is)
WO (1) WO2003006064A1 (is)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US8586092B2 (en) 2009-08-31 2013-11-19 Xi'an Libang Pharmaceutical Technology Co., Ltd. Fulvestrant nanosphere/microsphere and preparative method and use thereof
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
CN102600065B (zh) * 2012-03-31 2014-08-13 莱普德制药有限公司 一种氟维司群或其衍生物油性制剂及其制备方法
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
JP6682163B2 (ja) * 2016-04-06 2020-04-15 富士フイルム株式会社 医薬組成物
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
MX2018013414A (es) * 2016-05-06 2019-06-06 Eagle Pharmaceuticals Inc Formulaciones de fulvestrant y metodos para su uso.
CN109152785B (zh) 2016-05-31 2021-02-09 富士胶片株式会社 医药组合物
JP7220712B2 (ja) * 2017-11-08 2023-02-10 イーグル ファーマスーティカルズ、インク． フルベストラント製剤とその使用方法
US20210169897A1 (en) * 2017-12-07 2021-06-10 Nevakar Inc. Concentrated Fulvestrant Compositions
WO2019151353A1 (ja) * 2018-01-31 2019-08-08 富士フイルム株式会社 注射用製剤の製造方法
CN111481559B (zh) * 2019-01-25 2021-10-08 江苏恒瑞医药股份有限公司 一种高浓度的氟维司群组合物及其制备方法
US20220370359A1 (en) * 2019-12-11 2022-11-24 Shanghai Bocimed Pharmaceutical Co., Ltd. Fulvestrant pharmaceutical composition, preparation method therefor, and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy

Also Published As

Publication number Publication date
IS7097A (is) 2004-01-05
CA2453111A1 (en) 2003-01-23
JP2004534093A (ja) 2004-11-11
MXPA04000028A (es) 2004-05-21
WO2003006064A1 (en) 2003-01-23
CO5560585A2 (es) 2005-09-30
NO20040047L (no) 2004-02-23
RU2004102393A (ru) 2005-03-27
IL159576A0 (en) 2004-06-01
EP1406662A1 (en) 2004-04-14
HUP0400115A2 (hu) 2004-06-28
AR037138A1 (es) 2004-10-27
CN1553815A (zh) 2004-12-08
HUP0400115A3 (en) 2005-11-28
PL367624A1 (en) 2005-03-07

Similar Documents

Publication Publication Date Title
BR0107445A (pt) Formulação farmacêutica, uso de fulvestrante na preparação de uma formulação farmacêutica, e, seringa ou frasco
BR0210898A (pt) Formulação farmacêutica, dose unitária da mesma, uso de pulvestrante na preparação de uma formulação farmacêutica, e, seringa ou frasco estéril
AR098109A2 (es) Un análogo de epotilona, su uso para la preparación de un medicamento y una composición farmacéutica adecuada para administración parenteral
KR920700679A (ko) 비(nasal) 전달용 지질부형제와 그 사용법
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
JP2003519659A5 (is)
BR9811249A (pt) Nova formulação para inalação; apresentando densidade volumétrica, quando derramada, de 0,20 à 0,38g/ml, processo para preparação de formulação e uso da mesma
BR0208013A (pt) Mecanismo de acionamento para um dispositivo de injeção e dispositivo de injeção
BR9916829A (pt) Formulações aerossóis farmacêuticas contendo fluoroalcanos, budesonida e formoterol
BR9810729A (pt) Composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsionante
KR970704434A (ko) 약학적으로 안정한 옥살리플라티늄 제제(pharmaceutically stable oxaliplatinum preparation)
ES2253423T3 (es) Formulacion de un ester de testosterona para uso humano.
UY27533A1 (es) Composiciones farmacéuticas que contienen oxibutinina
KR970706021A (ko) N-치환-o-톨루이딘유도체로 이루어진 약용배합제 및 경피흡수형제제(MEDICINAL ADJUVANTS CONSISTIONG OF AN N-SUBSTITUED-o-TOLUIDING DERIVANTIVE, AND PERCUTANEOUSLY ABSORBALE PREPARATIONS COMPRISING THE ADJUVANTS)
CL2009001899A1 (es) Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01).
PT1256339E (pt) Sistema terapeutico transdermico para doenca de parkinson que induz niveis plasmaticos altos de rotigotina
SV2002000969A (es) Composicion parenteral reconstituible
BR0210595A (pt) Regime de dosagem e composição farmacêutica para contracepção de emergência
HRP20230929T1 (hr) Stabilni pripravci semaglutida i njihova upotreba
BR9916830A (pt) Formulações aerossóis farmacêuticas contendo fluoroalcanos e budesonide
WO2001047913A3 (de) Substituierte n-benzyl-indol-3-yl- glyoxylsäure-derivate antitumorwirkung
BR0008713A (pt) Processos para preparar formulações ecomposições farmacêuticas orais com ecb
KR920703112A (ko) 의약품 조성물
PT1305057E (pt) Composicao de biomateria microparticular para uso medicinal
AR008559A1 (es) Uso de pentosanpolisulfato (pps) o de una sal farmaceuticamente aceptable del mismo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A,5A,6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009.